Tyrosine kinase inhibitors improve parenchymal findings of liver cirrhosis in a patient exhibiting concomitant hepatocellular carcinoma and renal cell cancer.

Kus, Tulay; Aktas, Gokmen; Sevinc, Alper; Oktay, Cemil; Kalender, Mehmet Emin; Camci, Celaletdin

Kus, Tulay; Aktas, Gokmen; Sevinc, Alper; Oktay, Cemil; Kalender, Mehmet Emin; Camci, Celaletdin.

Afiliación

Kus T; Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey.
Aktas G; Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey.
Sevinc A; Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey.
Oktay C; Department of Radiology, School of Medicine, Akdeniz University, Antalya TR-07100, Turkey.
Kalender ME; Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey.
Camci C; Division of Medical Oncology, Department of Internal Medicine, Gaziantep Oncology Hospital, School of Medicine, Gaziantep University, Gaziantep TR-27310, Turkey.

Mol Clin Oncol ; 4(2): 290-292, 2016 Feb.

Article en En | MEDLINE | ID: mdl-26893877

Palabras clave

cirrhosis; hepatocellular carcinoma; renal cell cancer; sorafenib; sunitinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Mol Clin Oncol Año: 2016 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google